Timothy T. Richards Sells 10,000 Shares of ClearPoint Neuro, Inc. (NASDAQ:CLPT) Stock

ClearPoint Neuro, Inc. (NASDAQ:CLPT - Get Free Report) Director Timothy T. Richards sold 10,000 shares of the company's stock in a transaction that occurred on Tuesday, June 10th. The shares were sold at an average price of $13.28, for a total value of $132,800.00. Following the completion of the transaction, the director now directly owns 77,381 shares of the company's stock, valued at $1,027,619.68. This represents a 11.44% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this hyperlink.

ClearPoint Neuro Stock Down 4.1%

CLPT traded down $0.50 during trading on Friday, reaching $11.58. 222,641 shares of the stock traded hands, compared to its average volume of 243,573. ClearPoint Neuro, Inc. has a 12 month low of $5.11 and a 12 month high of $19.22. The stock's 50-day moving average is $12.79 and its 200 day moving average is $14.31. The stock has a market capitalization of $324.11 million, a PE ratio of -16.75 and a beta of 0.93.

ClearPoint Neuro (NASDAQ:CLPT - Get Free Report) last released its quarterly earnings data on Tuesday, May 13th. The company reported ($0.22) earnings per share for the quarter, missing the consensus estimate of ($0.15) by ($0.07). The company had revenue of $8.49 million during the quarter, compared to the consensus estimate of $8.21 million. ClearPoint Neuro had a negative net margin of 59.64% and a negative return on equity of 62.10%. As a group, equities research analysts anticipate that ClearPoint Neuro, Inc. will post -0.66 EPS for the current year.

Hedge Funds Weigh In On ClearPoint Neuro

Institutional investors and hedge funds have recently made changes to their positions in the stock. AlphaQuest LLC bought a new stake in ClearPoint Neuro in the 4th quarter valued at about $80,000. Deutsche Bank AG bought a new stake in shares of ClearPoint Neuro during the first quarter valued at approximately $63,000. Tower Research Capital LLC TRC bought a new stake in shares of ClearPoint Neuro during the fourth quarter valued at approximately $93,000. State of Wyoming acquired a new position in shares of ClearPoint Neuro during the fourth quarter worth approximately $145,000. Finally, Occudo Quantitative Strategies LP bought a new position in shares of ClearPoint Neuro in the 4th quarter worth $155,000. Institutional investors own 30.08% of the company's stock.

Wall Street Analysts Forecast Growth

CLPT has been the topic of several recent research reports. Wall Street Zen downgraded ClearPoint Neuro from a "hold" rating to a "sell" rating in a report on Thursday, May 22nd. Stifel Nicolaus upped their target price on ClearPoint Neuro from $19.00 to $25.00 and gave the company a "buy" rating in a report on Tuesday, April 1st.

ClearPoint Neuro Company Profile

ClearPoint Neuro, Inc operates as a medical device company primarily in the United States. It develops and commercializes platforms for performing minimally invasive surgical procedures in the brain under magnetic resonance imaging guided interventions. The company offers ClearPoint system, an integrated system for the insertion of deep brain stimulation electrodes, biopsy needles, and laser catheters, as well as the infusion of pharmaceuticals into the brain.